Phase 3 study for people with Hidradenitis Suppurativa

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting

Phase Phase 3

Sponsor Incyte Corporation

Registry number NCT06855498

Started 28 February 2025 Today 16 October 2026 Estimated completion 28 February 2028

Where this trial is running

Trial sites and the status recorded for each
Site	City	State or country	Status at this site
Investigative Site AU001	Charleston	NSW	Recruiting
Investigative Site AU003	Kogarah	NSW	Recruiting
Investigative Site AU005	Liverpool	NSW	Recruiting
Investigative Site AU010	Sydney	NSW	Recruiting
Investigative Site AU007	Woolloongabba	QLD	Not yet recruiting
Investigative Site AU002	Melbourne	VIC	Recruiting
Investigative Site AU011	Melbourne	VIC	Completed
Investigative Site AU008	Fremantle	Australia	Recruiting
Investigative Site AU009	Westmead	Australia	Not yet recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over

Sex Anyone, regardless of sex

Healthy volunteers Not accepted

Enrolment target 600

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Ability to comprehend and willingness to sign a written ICF for the study.

* Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.

* Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.

* Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.

* Willingness to avoid pregnancy or fathering children as defined in the protocol.

* Willingness and ability to comply with the study Protocol and procedures.

Exclusion Criteria:

* Had been permanently discontinued from study treatment during the parent study.

* Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.

* Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:

* Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).

* Live, attenuated vaccine.

* Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.

* Women who are pregnant (or who are considering pregnancy) or breastfeeding.

* Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.

* Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

* Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Dates on the record

Started 28 February 2025

Estimated completion 28 February 2028

Registry last updated 9 October 2026

Checked by Voxsanity 15 October 2026

Results, publications and the official record

No results are posted on the official record yet.
No publications are listed on the official record yet.
Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.

Sources and dates

ClinicalTrials.gov – the record this page reformats
ClinicalTrials.gov processing date: 9 October 2026.
This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.

Voxsanity

Clinical trials recruiting in Australia, from the public registries · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial, which may be relevant to my care:

Trial: NCT06855498

Sponsor: Incyte Corporation

Phase: Phase 3

Status: Recruiting

Condition: Hidradenitis Suppurativa

More information: https://clinicaltrials.gov/study/NCT06855498

Eligibility criteria, as the registry published them

Reproduced exactly, unedited. Written for researchers rather than for patients.

Inclusion Criteria:

Ability to comprehend and willingness to sign a written ICF for the study.
Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
Willingness to avoid pregnancy or fathering children as defined in the protocol.
Willingness and ability to comply with the study Protocol and procedures.

Exclusion Criteria:

Had been permanently discontinued from study treatment during the parent study.
Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
- Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
- Live, attenuated vaccine.
Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
Women who are pregnant (or who are considering pregnancy) or breastfeeding.
Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a registered health practitioner to access unapproved therapeutic goods for individual patients.

Not medical advice. Voxsanity reformats information published by public registries. It does not give medical advice and is not a substitute for talking to your doctor.